Posts

Macula month

May is Macula Month!

May is Macula Month and the ideal time to learn more about macular disease, what support is available to you, and to remind your friends and family members of the importance of looking after their vision!

Macular disease is the leading cause of blindness and severe vision loss in Australia. It includes age-related macular degeneration and diabetic eye disease, along with other less common diseases of the macula. Those over 50 are at higher risk of age-related macular degeneration, and everyone with diabetes is at risk of vision loss through diabetic eye disease.

Here at Focus Eye Centre, we have highly trained, and well respected professionals in the ophthalmology field. For more information on Macula Month, come in and see our retinal specialists, Dr Margaret Kearns and Dr Paula Berdoukas.

Learn More – A range of publications produced by Macular Disease Foundation Australia are available free of charge. Publications cover disease information, risk factors, symptoms, preventive measures, and a range of guides on low vision. Next time you visit Focus Eye Centre, ask about these free publications, or call the Foundation toll-free on 1800 111 709 to have these posted to you.

Support – Macular Disease Foundation Australia works alongside ophthalmology practices in support of patients, their family and carers. They offer free advice and support in living well with macular disease and can be contacted on the toll-free Helpline on 1800 111 709.

Having a regular eye test is the best way to detect changes in your vision, early diagnosis and timely treatment gives the best opportunity to save sight. If you, or a family member, notice any sudden changes in vision, call us immediately on 02 9663 3927.

For more information on Macula Month 2018, visit www.mdfoundation.com.au

amd

New treatment to fight against sight loss caused by AMD

Patients regain sight after being first to receive retinal tissue engineered from stem cells

  • Successful trial on patients using new stem cell based treatment for wet age-related macular degeneration (AMD).
  • Results from a clinical study suggest the treatment is safe and effective.
  • The study is a major milestone for the London Project to Cure Blindness and could lead to an ‘off-the-shelf’ treatment within five years.

The first patients to receive a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) have regained reading vision.

The results of this ground-breaking clinical study, published in Nature Biotech, described the implantation of a specially engineered patch of retinal pigment epithelium cells derived from stem cells to treat people with sudden severe sight loss from wet AMD. It is hoped that it will also help treat dry AMD in the future.

It’s the first description of a complete engineered tissue that has been successfully used in this way.

The study is a major milestone for the London Project to Cure Blindness, a partnership between Professor Pete Coffey from University College London and Professor Lyndon da Cruz, a retinal surgeon at Moorfields Eye Hospital NHS Foundation Trust.  The Project has also been supported by the UCL Institute of Ophthalmology and the National Institute for Health Research (NIHR).

AMD is the most common cause of sight loss in the UK, and can lead to a rapid loss of central (reading) vision. The two patients who underwent the procedure, a woman in her early 60s and a man in his 80s, had the severe form of the condition (wet AMD) and declining vision.

The study investigated whether the diseased cells at the back the patients’ affected eye could be replenished using the stem cell based patch. A specially engineered surgical tool was used to insert the patch under the retina in the affected eye of each patient in an operation lasting one to two hours.

The patients were monitored for 12 months and reported improvements to their vision. They went from not being able to read at all even with glasses, to reading 60-80 words per minute with normal reading glasses.

Photo of Douglas Waters, patient to receive trial treatment.

Douglas Waters, 86, from Croydon, London, was one of two people who had received the treatment at Moorfields Eye Hospital. He developed severe wet AMD in July 2015 and received the treatment three months later in his right eye. He says: “In the months before the operation my sight was really poor and I couldn’t see anything out of my right eye. I was struggling to see things clearly, even when up-close. After the surgery my eyesight improved to the point where I can now read the newspaper and help my wife out with the gardening. It’s brilliant what the team have done and I feel so lucky to have been given my sight back.”

Professor Lyndon da Cruz, consultant retinal surgeon at Moorfields Eye Hospital NHS Foundation Trust said:

“The results suggest that this new therapeutic approach is safe and provides good visual outcomes. The patients who received the treatment had very severe AMD, and their improved vision will go some way towards enhancing their quality of life. We recognise that this is a small group of patients, but we hope that what we have learned from this study will benefit many more in the future.”

Professor Pete Coffey, UCL Institute of Ophthalmology said:

“This study represents real progress in regenerative medicine and opens the door to new treatment options for people with age-related macular degeneration. We hope this will lead to an affordable ‘off-the-shelf’ therapy that could be made available to NHS patients within the next five years.”

Robert Dufton, chief executive of Moorfields Eye Charity said:

“The results from this trial are fantastic and the culmination of years of research by the London Project team. Philanthropy has played a critical role in the London Project since its inception and we are delighted that this support continues through Moorfields Eye Charity. This ground-breaking milestone demonstrates the real impact philanthropy plays in creating life-changing moments, such as helping someone regain their sight.”

Successful trials of new treatment at Moorfields in fight against sight loss caused by AMD

Intravitreal Injections

What types of conditions will benefit from Intravitreal Injections?

Intravitreal injections are used to deliver drugs to the retina and other structures in the back of the eye. Common conditions treated with intravitreal injections include macular degenerationdiabetic retinopathy, retinal vascular diseases and ocular inflammation.

Read more

eye conditions, macular degeneration simulation

Macular Degeneration – Causes, Symptoms, Diagnosis and Treatments

What is Macular Degeneration ?

The macula is a small central area of the retina. Structures in the macula are specialised for high acuity vision. The macula is important for reading, driving, recognition of faces and fine detail. Damage to the macula, such as Macular Degeneration, can lead to a loss of central vision.

Read more